Cue Biopharma, Inc. (CUE)Healthcare | Biotechnology | Boston, United States | NasdaqCM
16.71 USD
-1.96
(-10.498%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 16.50 -0.21 (-0.210%) ⇩ (Oct. 16, 2026, 5:08 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:05 a.m. EDT
Cue Biopharma presents a catastrophic long-term investment case driven by a brutal seven-year price collapse. The stock has lost nearly 90% of its value over the trailing window, with five consecutive years of negative annual returns, signaling a profound structural deterioration in market confidence regarding the business's viability. Fundamentally, the company is bleeding cash with negative operating margins, negative free cash flow, and a massive gap between its market capitalization and book value, suggesting the market views the equity as deeply impaired. While the analyst consensus is aggressively bullish with a target price significantly higher than the current level, this appears to be a speculative bet on a turnaround rather than a reflection of current operational reality. Short-term momentum remains weak despite a recent price bounce, as the stock trades well below its moving averages and the statistical forecast offers no directional edge. With no dividend to provide income and a balance sheet showing significant distress relative to its valuation, the security warrants avoidance. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.128534 |
| AutoETS | 0.130055 |
| MSTL | 0.137212 |
| AutoTheta | 0.222172 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.397 |
| Excess Kurtosis | 0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 133.203 |
| Revenue per Share | 8.311 |
| Market Cap | 121,388,352 |
| Forward P/E | -34.81 |
| Beta | 2.63 |
| Website | https://www.cuebiopharma.com |
As of Oct. 10, 2026, 5:05 a.m. EDT: Options activity is negligible and lacks meaningful liquidity. Call volume is concentrated deep in-the-money at strikes far below the current price, while put volume is minimal and scattered. This indicates a lack of active speculative positioning or hedging by institutional or retail players, rendering the options market ineffective for gauging immediate sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.32155907 |
| Address1 | 40 Guest Street |
| All Time High | 950.7 |
| All Time Low | 4.98 |
| Ask | 22.4 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 214,620 |
| Average Daily Volume3 Month | 272,406 |
| Average Volume | 272,406 |
| Average Volume10Days | 214,620 |
| Beta | 2.628 |
| Bid | 12.97 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.442 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.71 |
| Current Ratio | 1.255 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 18.87 |
| Day Low | 16.54 |
| Debt To Equity | 133.203 |
| Display Name | Cue Biopharma |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,724,099,400 |
| Earnings Call Timestamp Start | 1,724,099,400 |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,028,800 |
| Ebitda | -97,284,000 |
| Ebitda Margins | -2.58356 |
| Enterprise To Ebitda | -1.1 |
| Enterprise To Revenue | 2.843 |
| Enterprise Value | 107,051,360 |
| Eps Forward | -0.48 |
| Eps Trailing Twelve Months | -29.59 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 27.3534 |
| Fifty Day Average Change | -10.6434 |
| Fifty Day Average Change Percent | -0.38910705 |
| Fifty Two Week Change Percent | -32.155907 |
| Fifty Two Week High | 45.5 |
| Fifty Two Week High Change | -28.79 |
| Fifty Two Week High Change Percent | -0.6327473 |
| Fifty Two Week Low | 4.98 |
| Fifty Two Week Low Change | 11.73 |
| Fifty Two Week Low Change Percent | 2.3554215 |
| Fifty Two Week Range | 4.98 - 45.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,514,903,400,000 |
| Float Shares | 6,361,157 |
| Forward Eps | -0.48 |
| Forward P E | -34.8125 |
| Free Cashflow | -33,425,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Fullday Change | -2.17 |
| Fullday Change Percent | -11.622925 |
| Fullday Price | 16.71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -0.9915 |
| Gross Profits | -37,335,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15054 |
| Held Percent Institutions | 0.22799 |
| Implied Shares Outstanding | 7,264,414 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,776,988,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. |
| Long Name | Cue Biopharma, Inc. |
| Market | us_market |
| Market Cap | 121,388,352 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_417883814 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -164,108,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 229,192,261 |
| Number Of Analyst Opinions | 3 |
| Open | 18.57 |
| Operating Cashflow | -50,046,000 |
| Operating Margins | -11.133051 |
| Overall Risk | 7 |
| Phone | 617 949 2680 |
| Post Market Change | -0.20999908 |
| Post Market Change Percent | -1.2567271 |
| Post Market Price | 16.5 |
| Post Market Time | 1,792,184,881 |
| Previous Close | 18.67 |
| Price Hint | 2 |
| Price To Book | 37.805428 |
| Price To Sales Trailing12 Months | 3.2236981 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.074 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.96 |
| Regular Market Change Percent | -10.4981 |
| Regular Market Day High | 18.87 |
| Regular Market Day Low | 16.54 |
| Regular Market Day Range | 16.54 - 18.87 |
| Regular Market Open | 18.57 |
| Regular Market Previous Close | 18.67 |
| Regular Market Price | 16.71 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 105,195 |
| Return On Assets | -1.7266201 |
| Return On Equity | -16.03478 |
| Revenue Growth | 1.667 |
| Revenue Per Share | 8.311 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 7,264,414 |
| Shares Percent Shares Out | 0.0967 |
| Shares Short | 702,198 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 318,420 |
| Short Name | Cue Biopharma, Inc. |
| Short Percent Of Float | 0.1015 |
| Short Ratio | 1.7 |
| Source Interval | 15 |
| State | MA |
| Symbol | CUE |
| Target High Price | 115.0 |
| Target Low Price | 66.0 |
| Target Mean Price | 88.0 |
| Target Median Price | 83.0 |
| Total Cash | 17,414,000 |
| Total Cash Per Share | 2.397 |
| Total Debt | 3,077,000 |
| Total Revenue | 37,655,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -29.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.737326 |
| Two Hundred Day Average Change | -4.0273266 |
| Two Hundred Day Average Change Percent | -0.19420666 |
| Type Disp | Equity |
| Volume | 105,195 |
| Website | https://www.cuebiopharma.com |
| Zip | 2,135 |